Loading...
Please wait, while we are loading the content...
Similar Documents
Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Sundharam, J. Mohana |
| Copyright Year | 2006 |
| Abstract | Rituximab belongs to the class of biologicals and is a specific mouse and human chimeric monoclonal antibody. This IgG1 has a long half-life of 76 to 200 h and targets the CD20 antigen. The CD 20 antigen is present on pre-B, immature and mature B cells and is important for B-cell activation and proliferation. Binding of rituximab to CD 20 results in complementand antibody-dependent cytotoxicity and subsequent apoptosis of cells exhibiting this antigen. CD20 is not expressed on stem cells and plasma cells and hence depletion of the B-cell subpopulation is transient and does not affect immunoglobulin synthesis. Normal levels of total serum IgG are maintained and antibody levels against HSV 1/2 and VZV are not significantly affected after rituximab treatment. |
| File Format | PDF HTM / HTML |
| DOI | 10.4103/0378-6323.25656 |
| PubMed reference number | 16707836 |
| Journal | Medline |
| Volume Number | 72 |
| Issue Number | 2 |
| Journal | Indian journal of dermatology, venereology and leprology |
| Alternate Webpage(s) | http://www.bioline.org.br/pdf?dv06057 |
| Alternate Webpage(s) | https://doi.org/10.4103/0378-6323.25656 |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
